Gabizon, A. et al. (1982) “Liposomes as in Vivo Carriers of Adriamycin: Reduced Cardiac Uptake and Preserved Antitumor Activity in Mice,” American Association for Cancer Research, 42(11), pp. 4734–4739.
Gao, W. et al. (2013) “Liposome-like nanostructures for drug delivery,” Journal of Materials Chemistry B, 1(48), p. 6569. DOI: 10.1039/C3TB21238F Grenader, T. et al. (2012) “Pegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicin,” World Journal of Clinical Oncology, 3(10), p. 137. NIH [Online].
Kulkarni, S.A. and Feng, S.-S. (2013) “Effects of particle size and surface modification on cellular uptake and biodistribution of polymeric nanoparticles for drug delivery,” Pharmaceutical Research, 30(10), pp. 2512–2522. PubMed [Online].
Luminari, S. et al. (2010) “Nonpegylated liposomal doxorubicin (Myocet™) combination (R-comp) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): Results from the phase II EUR018 trial,” Annals of Oncology, 21(7), pp. 1492–1499. ScienceDirect [Online].
Shoji, T. et al. (2014) “A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study),” Cancer Chemotherapy and Pharmacology, 73(5), pp. 895–901. SpringerLink [Online].
Tardi, P., Boman, N. and Cullis, P. (1985) “Liposomal Doxorubicin,” Journal of Drug Targeting, 4(3), pp. 129–140.